Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

about

Cancer stem cells and evolving novel therapies: a paradigm shift.

P2860

Q50072739-D401E7E7-B01B-4717-9FDE-91612D0D9BD5

P2860

Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q45907759

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Expanded molecular interrogati ...... us non-small cell lung cancer.

@en

Expanded molecular interrogati ...... us non-small cell lung cancer.

@nl

type

Item

label

Expanded molecular interrogati ...... us non-small cell lung cancer.

@en

Expanded molecular interrogati ...... us non-small cell lung cancer.

@nl

prefLabel

Expanded molecular interrogati ...... us non-small cell lung cancer.

@en

Expanded molecular interrogati ...... us non-small cell lung cancer.

@nl

P1476

Expanded molecular interrogati ...... us non-small cell lung cancer.

@en

P2093

Claudia Seng

http://www.w3.org/2001/XMLSchema#string

Daniel S W Tan

http://www.w3.org/2001/XMLSchema#string

Kah Weng Lau

http://www.w3.org/2001/XMLSchema#string

Tony K H Lim

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Selective inhibition of BET bromodomains

Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases

Molecular biology of lung cancer: clinical implications

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

P304

372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2017.08.42

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29057232

http://www.w3.org/2001/XMLSchema#string

P932

5635263

http://www.w3.org/2001/XMLSchema#string

Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

about

P2860

P2860

Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932